Core Scientific Details Financial Restatement, Ongoing Clawback Analysis, & Board Changes in Proxy Statement
Summary
Core Scientific's proxy statement details a financial restatement, ongoing executive compensation clawback analysis, and significant board changes following low shareholder support for executive pay.
Key Events
-
Financial Restatement & Ongoing Clawback Analysis
The company restated financial statements for 2024 and 2025 interim periods due to improper asset capitalization, initiating an ongoing clawback analysis for executive incentive compensation. This follows the 10-K/A filing on March 18, 2026, which likely contained the restated financials.
-
Low Shareholder Support for Executive Pay
The 2025 say-on-pay vote received only 38.3% shareholder approval, prompting the company to increase performance-based equity (PSUs) to 67% of long-term incentive grants for 2025.
-
Executive Compensation Decisions
Despite low say-on-pay support, the CEO received a 32% base salary increase to $825,000, and annual cash bonuses for eligible NEOs were paid at 200% of target for 2025 performance.
-
Board Composition Changes
Chairman Jordan Levy will not stand for re-election, and the board size will be reduced to five members. New independent directors will be appointed in consultation with Two Seas Capital, as per a February 2026 cooperation agreement, which was previously hinted at in the SCHEDULE 13D/A on March 21, 2026.
Analysis
This definitive proxy statement reveals significant corporate governance and financial issues. The company disclosed a financial restatement for 2024 and 2025 interim periods due to improper asset capitalization, leading to an ongoing clawback analysis for executive incentive compensation. This follows a low 38.3% shareholder support for the 2025 say-on-pay vote, prompting a shift to more performance-based equity awards. Additionally, the Chairman will not seek re-election, and the board size will be reduced, with new independent directors to be appointed in consultation with activist investor Two Seas Capital. These events highlight past financial control weaknesses and significant shareholder dissatisfaction, despite the company's strategic shift towards HPC/AI infrastructure.
At the time of this filing, CORZ was trading at $14.96 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $6.20 to $23.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.